The Rong En Group announced on April 3 that its wholly-owned subsidiary, Sheng Shi Rong En Biotech Co., Ltd. (hereinafter referred to as 'Reon Biological'), and the Japanese company IDPharma Co., Ltd., (hereinafter referred to as 'IDP' ) Signed a Patent Technology Licensing Contract. The company obtained the right to use the Sendai virus vector to induce artificial induced stem cells (hereinafter referred to as 'iPS') to use the intellectual property rights of cell reprogramming technology to carry out commercial activities in the licensed area.
